Top Markets
Coin of the day
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
Classement en actions #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Prix de l'action
$0.69158324
Capitalisation boursière
$9.84M
Changement (1 jour)
0.00%
Changement (1 an)
-84.15%
Pays
JP
Échange Delta-Fly Pharma, Inc. (4598)

Catégorie

EPS pour Delta-Fly Pharma, Inc. (4598)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Delta-Fly Pharma, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Delta-Fly Pharma, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE